A body of evidence is emerging that shows a requirement for ephrin ligands in the proper migration of cells, and the formation of cell and tissue boundaries. These processes are dependent on the cell-cell adhesion system, which plays a crucial role in normal morphogenetic processes during development, as well as in invasion and metastasis 1-9 . Although ephrinB ligands are bi-directional signalling molecules, the precise mechanism by which ephrinB1 signals through its intracellular domain to regulate cell-cell adhesion in epithelial cells remains unclear. Here, we present evidence that ephrinB1 associates with the Par polarity complex protein Par-6 (a scaffold protein required for establishing tight junctions) and can compete with the small GTPase Cdc42 for association with Par-6. This competition causes inactivation of the Par complex, resulting in the loss of tight junctions. Moreover, the interaction between ephrinB1 and Par-6 is disrupted by tyrosine phosphorylation of the intracellular domain of ephrinB1. Thus, we have identified a mechanism by which ephrinB1 signalling regulates cell-cell junctions in epithelial cells, and this may influence how we devise therapeutic interventions regarding these molecules in metastatic disease.
It has been known for over a decade that ephrinBs are bi-directional signalling molecules that can signal through their intracellular domains to regulate cell-cell boundaries and adhesion 10, 11 . EphrinB has been shown to interact with proteins that control cell migration through a G-protein-coupled receptor 12 , or by co-opting Dishevelled, a scaffold protein from the Wnt signalling pathway 13 . EphrinB can also regulate the actin cytoskeleton and cell morphogenesis through the adaptor protein Grb4/Nck2 and the G-protein-coupled receptor kinase-interacting protein 1 (ref. 14) . It has also been shown that communication through gap junctions may be regulated by ephrinB1 through an interaction with connexin43 (ref. 15) . Here, we provide mechanistic insight indicating that ephrinB1 regulates cell-cell junctions through the Par (partitioning defective) protein complex, which has a central role in tight junction formation, cell-cell adhesion and cell polarity during embryogenesis 16 .
We present evidence that Par-6 has a crucial role in the ability of ephrinB1 to regulate tight junction formation. Par-6 is a major scaffolding protein that constitutively binds atypical protein kinase C (aPKC) through its PB1 (Phox and Bem 1) domain; binding stimulates a conformational change in an active Cdc42-GTP, causing aPKC activation 17 . The localized activity of the Par-6/aPKC/Cdc42-GTP complex to the apical cell junctions regulates tight junction formation, and tight junction complexes are believed to associate with the actin cytoskeleton, which is reorganized for the formation and maintenance of cell-cell contacts 18 . Several lines of evidence suggest that Par-6 may be a candidate mediator of ephrinB1 signalling. Such evidence includes significant overlap between Par-6 and ephrinB1 RNA expression during development (data not shown), and overlap in protein localization of exogenously expressed proteins along cell-cell boundaries in epithelial cells of the ectoderm in early gastrulae-stage embryos (Fig. 1a, b) . Moreover, immunoprecipitation analyses of lysates from Xenopus laevis oocytes exogenously expressing ephrinB1 and various individual members of the Par polarity complex, identified Par-6 as specifically present in immunoprecipitates of ephrinB1 (Fig. 1c) , but not other members of the Par complex (Cdc42, Par-3 or PKCλ; Supplementary Information, Fig. S1a, b) . Finally, a bacterially expressed protein consisting of the amino-terminal portion of Par-6 (His-Flag-Par-6) was detected in an immunocomplex of a bacterially expressed protein consisting of the cytoplasmic domain of ephrinB1 fused to GST ( Supplementary Information, Fig. S1c ), suggesting the interaction may be direct.
To assess whether endogenous ephrinB1 and Par-6 proteins interact with each other, we conducted an immunoprecipitation analysis of ephrinB1 from lysates of HT29 colon carcinoma cells that express abundant levels of Par-6 and ephrinB1. Par-6 was present in ephrinB1 immunocomplexes, and in reciprocal immunoprecipitates, ephrinB1 was found in the Par-6 immunocomplexes, but not in the control Myc immunocomplexes (Fig. 1d ). These data indicate that an in vivo interaction exists between ephrinB1 and the Par-6 protein.
As the preceding experiments indicate that ephrinB1 can interact with Par-6, we sought to identify which region of ephrinB1 is necessary for binding to Par-6. We performed an immunoprecipitation analysis on lysates from oocytes co-expressing wild-type and carboxy-terminal deletion constructs of ephrinB1 along with wild-type Par-6. We found that deletion of 16 amino acids from the C terminus of ephrinB1 (ephrinB1 ∆16 ) prevents the interaction with Par-6 ( Supplementary  Information, Fig. S2a) . Involvement of a possible cryptic PDZ-binding motif (amino acids 309-312) was eliminated using mutants lacking the known and cryptic PDZ-binding motifs in vivo and in vitro ( Supplementary Information, Fig. S2b, c) .
Both Cdc42-GTP and Par-3 bind to Par-6 through the semi-CRIB-PDZ (semi-Cdc42/Rac-interacting binding-Postsynaptic density-95/discs large/zonula occludens-1) domain of 20) . Immunoprecipitation was performed with ephrinB1 and Par-6 deletion constructs, and only a construct retaining all three functional domains (PB1, semi-CRIB and PDZ) of Par-6 was able to bind ephrinB1 ( Supplementary Information, Fig. S2d ). These data suggest that the appropriate conformation of Par-6 or additional Par-6 interacting proteins may be necessary for a physical interaction between ephrinB1 and Par-6.
Having established that an interaction between ephrinB1 and Par-6 exists in vivo (Fig. 1d) , we performed loss-of-function studies in Xenopus embryos using antisense morpholino oligonucleotides (MOs) to block the expression of endogenous ephrinB1 or Par-6. We injected both blastomeres of 2-cell-stage embryos with ephrinB1MO or Par-6MO. MOs that block translation of the endogenous ephrinB1 caused a redistribution of tight junction-associated proteins, zonula occluden-1 (ZO-1) and cingulin, but left intact the lateral expression of lethal giant larvae 2 (Lgl2; Fig. 2a) . Thus, the localization of these proteins to tight junctions, as shown by immunofluorescence microscopy, was markedly reduced. Introduction of EphrinB1 WT∆UTR (an RNA resistant to the ephrinB1MO) at an appropriate level in embryos, was capable of rescuing the expression of wildtype ephrinB1, resulting in restoration of the proper localization of tight junction-associated proteins (Fig. 2b) . As expected, similar results were obtained with Par-6MO ( Supplementary Information, Fig. S3a, b) .
Several proteins affecting scaffold function have similar loss-or gain-offunction phenotypes 13, [21] [22] [23] ( Supplementary Information, Fig. S3c ), which may be caused by either preventing the formation of signalling centres or sequestering individual members of a signalling complex, respectively. As ephrinB1 acts as a signalling platform with no intrinsic activity of its own, similarly to Par-6, the levels of wild-type and mutant ephrinB1 RNAs must be carefully titrated in all of the ephrinB1MO rescue experiments and ephrinB1 overexpression studies ( Supplementary Information, Fig. S8a ). Thus, we tested whether overexpression of ephrinB1 affects tight junction formation in early embryonic ectoderm. Interestingly, injection of ephrinB1 RNA at levels above those required to replace endogenous ephrinB1 in our rescue experiments also resulted in disruption of ZO-1 localization at the tight junctions in early embryonic epithelial cells (Fig. 2c) ; however, localization of Lgl2 was unaffected ( Supplementary  Information, Fig. S3d ). Transmission electron microscopy (TEM) and dye permeability assays on embryos injected with ephrinB1MO or overexpressing ephrinB1 confirm the structural and functional loss of tight junctions (Fig. 2d , e, respectively). As expected, more toluidine blue dye permeates the animal pole ectodermal layer of MO-injected and ephrinB1-overexpressing embryos, indicating that tight junctions and cell-cell junctions are functionally compromised (Fig. 2e) . Moreover, although the localization of tight junction-associated proteins was altered, their expression levels remained constant in the presence of ephrinB1MO or ephrinB1 overexpression; similar results were observed for Par-6MO and Par-6 overexpression ( Supplementary Information, Fig. S3e ). These findings demonstrate that endogenous ephrinB1 is crucial for maintaining appropriate localization of tight-junction-associated proteins and that overexpression of ephrinB1 can influence tight-junctions by re-localizing these proteins and disrupting cell-cell boundaries.
One possibility of how ephrinB1 may normally regulate tight junctions is by its interaction with the Par polarity complex, and when inappropriately expressed, ephrinB1 may compete with other members with ephrinB1 for binding to Par-6. As increasing amounts of CA Cdc42 were expressed in Xenopus oocytes, decreasing amounts of ephrinB1 were found associated with Par-6 in immunocomplexes (Fig. 3a) . To confirm this result, we performed a reciprocal experiment, maintaining constant levels of Par-6 and CA Cdc42 expression, but increasing ephrinB1 expression. In this case, increasing amounts of ephrinB1 were observed in Par-6 immunoprecipitations, whereas the amount of CA Cdc42 in the immunocomplex correspondingly decreased (Fig. 3a) . No such competition was observed with increasing amounts of Par-3 or PKCλ in Par-6 immunocomplexes ( Supplementary Information, Fig. S4 ). These results indicate that ephrinB1 and active Cdc42 compete for interaction with Par-6, suggesting that this may be one of the mechanisms used by ephrinB1 to disrupt tight junctions. One prediction of the ephrinB1/Cdc42-GTP competition model is that the disruption of tight junctions observed with ephrinB1 overexpression in vivo ( Fig. 2c-e; Supplementary Information Fig. S9a ) may be rescued by compensatory expression of active Cdc42. In Xenopus embryonic ectoderm, appropriate expression of CA Cdc42 rescued tight junction localization of ZO-1 that was disrupted as result of ephrinB1 expression (Fig. 3b) . In contrast, an inactive Cdc42 (DN Cdc42; which cannot bind to Par-6) failed to rescue ZO-1 localization to tight junctions ( Fig. 3b; Supplementary Information, Fig. S8b, c) .
We tested whether the competition model may also function in the loss of cell-cell adhesion. It has been previously reported that overexpression of ephrinB1 causes a visible cell-dissociation phenotype in the embryonic ectoderm 10, 11 . We found that overexpression of Par-6 yields a similar phenotype ( Supplementary Information, Fig. S5 ). Expression of CA Cdc42 blocked Par-6-induced cell dissociation, consistent with a role for the active Par-6/Par-3/aPKC/Cdc42-GTP complex in maintaining cell-cell adhesion. In contrast, overexpressing either ephrinB1 WT or ephrinB1
∆15
,which retains the ability to bind Par-6, could markedly inhibit the rescue of cell-cell adhesion by CA Cdc42, whereas ephrinB1 ∆16 failed to do so ( Supplementary Information, Fig. S5 ). Collectively, these in vivo data support the biochemical analysis, indicating that ephrinB1 and active Cdc42 compete for binding to Par-6, and represents a mechanism by which ephrinB1 can influence tight-junctions and cell-cell adhesion.
EphrinB1 can be tyrosine phosphorylated in response to binding a cognate Eph receptor 24, 25 or the tight-junction-associated protein Claudin 26 or in response to FGF-receptor activation 10 . When an active FGF receptor 1 (FGFR1 KE) was expressed in Xenopus embryos, phosphorylated ephrinB1 localization was enriched at the apical cell junction, as shown by immunofluorescence microscopy using phospho-specific antibodies (Fig. 4a) . Interestingly, immunoprecipitation and western blot analysis of ephrinB1 indicates that phosphorylated ephrinB1 fails to interact with Par-6 (Fig. 4b) . Co-expression of FGFR1 KE with ephrinB1, Par-6 and CA Cdc42 restored the interaction between CA Cdc42 and Par-6 in immunoprecipitations (Fig. 3a , last lane), supporting this concept. Together, these data indicate that FGF receptor-induced phosphorylation can block the interaction between ephrinB1 and Par-6, and may regulate this interaction at tight junctions ( Supplementary Information, Fig. S9a) .
As ephrinB1 is known to be tyrosine phosphorylated on binding to the ectodomain of its cognate Eph receptor, we tested whether this event would also disrupt the association between ephrinB1 and Par-6. Co-immunoprecipitation analysis of endogenous ephrinB1 or Par-6 in HT29 cells in the presence of the EphB1 ectodomain fused to human Fc (EphB1-Fc) demonstrated a clear reduction in the ephrinB1-Par-6 association ( Supplementary Information, Fig. S6a) . Similar results were obtained with exogenously expressed proteins in embryo extracts that also exogenously express the cognate EphB1 receptor lacking a kinase domain (EphB1 ∆C ; Supplementary Information, Fig. S6b ). To determine which specific tyrosine residues within ephrinB1 are important for the phosphorylation-dependent dissociation of the ephrinB1/Par-6 complex, several mutants harbouring substitutions of Phe for Tyr in the intracellular domain of ephrinB1 were generated, coexpressed with Par-6 and FGFR1 KE, and tested in co-immunoprecipitation experiments. An ephrinB1 mutant for Tyr 310 (ephrinB1
Y310F
) did not dissociate from Par-6 in the presence of FGFR1 KE (Fig. 4c) , indicating that phosphorylation of ephrinB1 on Tyr 310 prevents or disrupts the interaction between ephrinB1 and Par-6. We tested whether this tyrosine phosphorylation event regulates the ability of ephrinB1 to influence proteins associated with tight junctions in vivo. As expected, overexpression of ephrinB1 caused loss of ZO-1 expression localized to tight junctions (Fig. 5a ). This phenotype was unaffected by kinase-dead FGFR1 (FGFR1 KD), but was rescued by FGFR1 KE (Fig. 5a) , and by co-expression of the truncated cognate receptor EphB1 ∆C ( Supplementary Information, Fig. S6c ). Interestingly, a substantial portion of ephrinB1 phosphorylated in response to these proteins was enriched in the tight junctions ( Supplementary Information,  Fig. S6c, d) . Furthermore, FGFR1 KE failed to rescue the appropriate localization of ZO-1 to tight junctions when the ephrinB1 Y310F mutant was expressed in ectoderm (Fig. 5a) . Together, the in vivo and physical interaction data indicate that Tyr 310 phosphorylation regulates tight junction formation by dissociating ephrinB1 from Par-6.
As further in vivo evidence for a role of Tyr 310 in the dissociation of the ephrinB1-Par-6 complex, we performed ephrinB1 replacement experiments. In these studies, translation of endogenous ephrinB1 was blocked by the ephrinB1MO, and wild-type (ephrinB1 WT∆UTR ) or mutant ephrinB1 RNAs (ephrinB1
Y310F∆UTR
) that are resistant to the MO were introduced at carefully titrated concentrations. Both of these proteins are expressed at levels that allow ephrinB1
WT to rescue the localization of tight junction-associated protein ZO-1 in the presence of the ephrinB1MO ( Fig. 5b ; Supplementary  Information, Fig. S8a ). In contrast, expression of the ephrinB1 Y310F mutant in the presence of ephrinB1MO failed to restore appropriate localization of the tight junction-associated protein ZO-1 (Fig. 5b) . These data indicate that a Tyr 310 in ephrinB1 is necessary for the proper maintenance of tight junctions, and is consistent with a phosphorylation event at this position causing dissociation of the ephrinB1-Par-6 complex.
From these data, one may predict that overexpression of ephrinB1 in the embryonic ectoderm, which causes disruption of the Cdc42-GTPPar-6 interaction, would reduce aPKC activity, whereas phosphorylation of ephrinB1 may rescue this activity. Indeed, overexpression of ephrin-B1
WT caused a marked reduction in aPKC activity towards a Par-3 substrate, as well as a decrease in the associated phosphorylation of aPKC. In contrast, the presence of FGFR1 KE or EphB1
∆C rescued aPKC activity ( Supplementary Information, Fig. S7a ), indicating that phosphorylation of ephrinB1 is essential for aPKC activation and proper functioning of the Par polarity complex at tight junctions. As expected, loss of endogenous ephrinB1, which results in disruption of tight junctions, also reduced aPKC activity, as shown by phospho-aPKC western blot analysis ( Supplementary Information, Fig. S7b ).
Another prediction from this model is that ephrinB1 phosphorylation at Tyr 310 may be necessary for the rescue of aPKC activity by FGFR1 KE. The presence of FGFR1 KE rescued aPKC activity, which was l e t t e r s reduced by ephrinB1 overexpression, but not in the case of the ephrin-B1 Y310F mutant (Fig. 5c ). These data indicate that phosphorylation of ephrinB1 on Tyr 310 is crucial for aPKC activation and proper functioning of the Par polarity complex at tight junctions. Collectively, our data demonstrate that ephrinB1-induced displacement of active Cdc42 from Par-6 can cause disruption of tight junctions, but Tyr phosphorylation of the intracellular domain of ephrinB1 inhibits the ephrinB1-Par-6 interaction, which results in the proper establishment of tight junctions ( Supplementary Information, Fig. S9a, b) .
There is compelling evidence that Eph/ephrin signalling has a crucial role in the control of cell-cell adhesion complexes 5, 9, 27 and morphogenetic processes that rely on the orderly formation of apical junctional complexes. Deregulation of this system in adult tissues can lead to malignant invasion and metastasis. A recent report shows that EphB receptors compartmentalize the expansion of colorectal cancer cells through cell-cell adhesion mechanisms, and this restricts the spreading of EphB-expressing tumour cells into ephrin-B1-positive territories in vitro and in vivo 28 . This restriction of invasion is dependent on forward signalling through the EphB receptor 28 . Our study supports this concept by raising the possibility that when ephrinB1 is deregulated or unphosphorylated in surrounding cells, tight junctions and cell-cell boundaries are compromised and allow invasion of tumour cells into this adjacent territory. Indeed, loss of EphB receptors has been reported in colorectal cancer cells 28 , Here we present data that ephrin has a role in tight junction integrity and can regulate tight junctions through the Par complex. A question remains as to whether loss of ephrinB1 results in tight junction disruption because of increased availability of Par-6, which then forms nonfunctional tight junction complexes, similarly to overexpression of Par-6 (refs 29, 30; Supplementary Information, Fig. S3 and S9c). Alternatively, it is possible that loss of ephrinB1 may disrupt the appropriate localization of the site at which tight junctions form, or that disruption of the interaction between ephrinB1 and connexin43 at gap and adherens junctions 15 disrupts cell adhesion and affects tight junctions. Understanding how the role of ephrin in polarity complexes and adhesion complexes are coordinated to control cell-cell adhesion and boundaries is likely to have implications in morphogenetic disorders and metastatic disease.
METHODS
Plasmids and reagents. cDNA clones encoding full-length Par-6, Par-3 and PKCλ were obtained from ATCC (GenBank ID: BC073237, NM_001092545 and NM_001090599). The ephrinB1MO has been described previously 31 . The Par-6MO was 25 nucleotides long with the respective base composition 5´-GGACTTACTAAAGCTGCGGTTCATC-3´ (Gene Tools). Various HA-tagged mutants of ephrinB1 (Y310F, V312A, ∆4, ∆4V312A, ∆15, ∆16, ∆17, ∆18 and ∆19) and HA-tagged deletion mutants of Par-6 (PB1, PDZ, CRIB-PDZ, PB1-CRIB-PDZ and C-ter) were generated by PCR and subcloned into pCS2 + . To determine whether tyrosine phosphorylation affects the ephrinB1-Par-6 association, FGFR1 KE (FGFR1 K562E), FGFR1 KD (FGFR1 C289R/K420A) and EphB1
∆C -Flag (amino acids 1-675) constructs in pCS2 + were used.
Embryo injections. Xenopus embryos were obtained by standard methods 32 . For injections, synthetic capped mRNAs were made using the SP6 mMessage mMachine kit (Ambion), and microinjected into embryos, as described previously 10 . For the rescue of MO effects, MO-resistant mRNAs representing ephrinB1 ∆UTR , and 4MT Par-6, which lack the 5´ UTR or contain 4 point-mutations in wobble codons following the ATG start, were synthesized. MOs and/or mRNAs were microinjected into each blastomere of 2-cell-stage embryos.
Immunoprecipitation and western blot analysis. EphB1-Fc (R&D Systems) was clustered using human immunoglobulin, as described previously 33 , and added to the HT29 cell culture medium at a concentration of 2.5 g ml -1 for 30 min. HT29 cells, oocytes, embryos or ectodermal explants were prepared with ice-cold lysis buffer as previously described 10 . Immunoprecipitations were conducted for 1 h on HT29 cell extracts or 15 oocyte (embryos) equivalents with antibody raised against HA, Flag (Applied Biological Materials), ephrinB1, Par-6 and protein-A/G agarose (Santa Cruz Biotechnology). Washes and immunoblots were performed as described previously 10 using anti-Flag-HRP conjugated (Sigma), anti-HA-HRP conjugated (Roche), antiphosphotyrosine-HRP conjugated (Upstate Biotechnology), anti-ephrinB1 (R&D Systems) or anti-Par-6 (Santa Cruz Biotechnology) antibodies. Lysates of ectodermal explants were immunoblotted with anti-phospho-aPKC (Cell Signaling Technology), anti-aPKC (Santa Cruz Biotechnology), anti-ZO-1, anti-Cingulin (Invitrogen) and anti-ERK2 (Santa Cruz Biotechnology) antibodies. All antibodies were diluted 1:1000, except for anti-phosphotyrosine-HRP, which was diluted 1:10,000.
Immunofluorescence microscopy. Xenopus embryos were collected at stage 10.5 and immunofluorescence microscopy was carried out as described previously 
Transmission electron microscopy (TEM).
Xenopus embryos were collected at stage 10.5 and fixed in 4% formaldehyde and 2% glutaraldehyde in 0.1 M cacodylate buffer and processed for thin-section TEM analysis. Briefly, the embryos are washed in the same buffer and post-fixed in osmium tetroxide (1% in same buffer) for 1 h. The embryos were washed in cacodylate buffer and in acetate buffer (0.1 M, pH 4.2), then en bloc stained in 0.1% uranyl acetate for 1 h and dehydrated in a series of ethanol (for example, 35, 50, 75, 95 and 100%) followed by three changes in propylene oxide. The embryos were infiltrated in an equal volume of propylene oxide and epoxy resin overnight, embedded in pure resin and cured at 55 °C for 48 h. Embryos in the proper orientation were thin-sectioned at 75 nm, mounted on a copper meshed grid and stained in uranyl acetate and lead citrate before TEM examination. Digital images were taken on the H7600 microscope equipped with an AMT camera.
Dye permeability assay. Xenopus embryos were collected at stage 9.5 and 10.5 and dehydrated in 25, 50, 75 and 100% methanol series. Embryos were then rehydrated by reversing the same methanol series, washed with 1×PBS, and stained with 0.01% toluidine blue (Sigma) for 7 min as described previously 35 .
In vitro kinase assays for aPKC. Xenopus ectodermal explants were collected at stage 10.5 and prepared with ice-cold lysis buffer as described previously 10 . aPKC immunoprecipitates were washed with ice-cold lysis buffer and kinase buffer (50 mM Tris-Cl (pH 7.4), 10 mM MgCl 2 , 1 mM dithiothreitol). Samples of 10 µl were used for immunoblotting with anti-phospho-aPKC antibody (Cell Signaling Technology), and the remaining sample was incubated with GST-Par-3 (amino acids 688-9735, 5 µg) in kinase buffer containing γ-32 P ATP (10 µCi) at 30 °C for 30 min. The reactions were stopped by adding 1× SDS-PAGE sample buffer and heating to 100 °C. The reaction products were resolved using SDS polyacrylamide (10%) gels and subsequently stained, destained and dried before autoradiography.
In vitro binding assays. Bacterially purified GST-ephrinB1-cyto or in vitro translated ephrinB1 (cytoplasmic domain) were incubated with the same amount of purified His-Flag-Par-6 in 750 µl of binding buffer (20 mM Tris-Cl (pH 8.0), 200 mM NaCl, 10 mM protease inhibitor cocktail) at 4 °C for 2 h. Immunoprecipitations were conducted for 1 h with antibody raised against GST (Santa Cruz Biotechnology). Washes and immunoblots were performed as described previously 10 using anti-Flag-HRP conjugated (Sigma) and anti-GST (Santa Cruz Biotechnology) antibodies. Gastrulae stage (St. 10.5) embryos were harvested and the percentage of embryos with cell dissociation determined. Cell dissociation was determined to be present when 10 -30% (mild), or over 30% (severe) of the ectodermal surface showed phenotypic cell-cell de-adherence (see histogram). Data are shown as mean ± s.d.
Figure S6
The interaction between ephrinB1 and Par-6 is disrupted in response to binding the cognate EphB1 receptor in vivo and in vitro. (a) EphB1-Fc was clustered using human Ig, and added to the HT 29 cell culture medium. Immunoprecipitates using anti-ephrinB1 (rabbit), anti-Par-6 (rabbit) or anti-c-Myc (rabbit) antibodies in HT29 cell lysates were immunoblotted with anti-Par-6 (goat), anti-phosphotyrosine-HRP conjugated, and anti-ephrinB1 (goat) antibodies. Lysates were analyzed directly by SDS-PAGE and immunoblotted with indicated antibodies to reveal endogenous expression levels of ephrinB1 and Par-6, respectively. Information Fig. S3, S6) , loss of ephrinB1 could effectively result in a similar effect. 
